UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 25, 2019

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware

1-3619

13-5315170

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

235 East 42nd Street

New York, New York

(Address of principal executive offices)

10017

(Zip Code)

Registrant's telephone number, including area code:

(212) 733-2323

Not Applicable

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:

[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07

Submission of Matters to a Vote of Security Holders

(a) The Pfizer Inc. (the "Company") Annual Meeting of Shareholders was held on April 25, 2019.

(b) Shareholders voted on the matters set forth below.

1. The nominees for election to the Company s Board of Directors were elected to hold office until the Company s next Annual Meeting of Shareholders, based upon the following votes:

Nominee

Votes For

Votes Against

Abstentions

Broker non-vote

Ronald E. Blaylock

3,912,479,252

78,594,255

11,037,194

887,836,749

Albert Bourla

3,968,299,845

23,724,642

10,086,214

887,836,749

W. Don Cornwell

3,792,127,947

199,713,095

10,264,240

887,836,749

Joseph J. Echevarria

3,824,294,719

167,540,269

10,276,108

887,836,749

Helen H. Hobbs

3,960,013,945

33,120,500

8,974,658

887,836,749

James M. Kilts

3,856,874,668

135,060,973

10,175,455

887,836,749

Dan R. Littman

3,959,418,600

32,811,206

9,881,290

887,836,749

Shantanu Narayen

3,948,229,994

43,833,811

10,047,291

887,836,749

Suzanne Nora Johnson

3,878,704,857

114,112,491

9,293,748

887,836,749

Ian C. Read

3,948,620,315

41,924,275

11,566,505

887,836,749

James C. Smith

3,941,173,326

50,720,278

10,217,492

887,836,749

2. The proposal to ratify the selection of KPMG LLP as the Company s independent registered public accounting firm for the 2019 fiscal year was approved based upon the following votes:

Votes for approval

4,701,180,439

Votes against

175,867,847

Abstentions

12,887,303

Broker non-votes

n/a

3. The proposal to approve, on an advisory basis, the compensation of the Company's Named Executive Officers was approved based upon the following votes:

Votes for approval

3,764,667,463

Votes against

200,933,424

Abstentions

36,509,563

Broker non-votes

887,836,749

4. The proposal to approve the Pfizer Inc. 2019 Stock Plan was approved based upon the following votes:

Votes for approval

3,439,109,067

Votes against

540,573,214

Abstentions (Have the same effect as a vote against this proposal under New York Stock Exchange rules)

22,428,815

Broker non-votes

887,836,749

5. The shareholder proposal regarding right to act by written consent was not approved based upon the following votes:

Votes for approval

494,345,288

Votes against

3,478,617,639

Abstentions

29,142,088

Broker non-votes

887,836,749

6. The shareholder proposal regarding report on lobbying activities was not approved based upon the following votes:

Votes for approval

1,179,442,668

Votes against

2,780,664,931

Abstentions

42,003,373

Broker non-votes

887,836,749

7. The shareholder proposal regarding independent chair policy was not approved based upon the following votes:

Votes for approval

1,067,318,698

Votes against

2,909,751,046

Abstentions

25,039,598

Broker non-votes

887,836,749

8. The shareholder proposal regarding integrating drug pricing into executive compensation policies and programs was not approved based upon the following votes:

Votes for approval

1,132,357,518

Votes against

2,814,700,448

Abstentions

55,053,129

Broker non-votes

887,836,749

(c) Not applicable

(d) Not applicable

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.

PFIZER INC.

Dated: April 29, 2019

By: /s/ Margaret M. Madden

Margaret M. Madden

Title: Senior Vice President & Corporate Secretary

Chief Governance Counsel